All In Biotech

Drug Trial Radar · NCT05312697

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Apr 28, 2022

Primary completion

Jul 7, 2022

Study completion Jul 7, 2022

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma
First posted
Apr 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).

Conditions

  • Osteogenesis Imperfecta

Interventions

  • SetrusumabBiological

    A fully human anti-sclerostin monoclonal antibody (mAb)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Retreatment Baseline in Lumbar Spine Bone Mineral Density (BMD) Measured by Dual-Energy X-Ray Absorptiometry (DXA) After 12 Months of SetrusumabTime frame: Retreatment Baseline, Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Mexico Clinical Research & Osteoporosis Center

    Albuquerque, New Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.